ClinicalTrials.gg
Not yet recruitingNCT07319858Updated Apr 21, 2026

The Effect of Using Multifunctional Baby Carrier With Heart Surgery

An interventional study of Multifunctional Baby Carrier in Congenital Heart Surgery, sponsored by Istanbul University - Cerrahpasa. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 1 Day to 3 Months. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Istanbul University - Cerrahpasa · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
1 Day to 3 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Pain by Istanbul University - Cerrahpasa — 13 open to participants now, 14 under way, none of them phase 3. Pain · Istanbul University - Cerrahpasa.

Planned enrollment
37th of 51
52 · median 80
Started
2026
with 4 others
No phase
50 of 54
10 open now
Primary completion
2027-08
later than 11 of 13 live
Registered
46th of 54
by date

Among the 54 studies in Pain by Istanbul University - Cerrahpasa, this one is the 37th largest by planned enrollment of the 51 interventional ones that give a count, is one of 5 that started in 2026, is one of 50 with no phase, reaches primary completion later than 11 of the 13 other live ones, and was the 46th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

13 of the 54 studies in Pain by Istanbul University - Cerrahpasa are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 1 Day to 3 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Pain by Istanbul University - Cerrahpasa, or all of them as a file.
02

Study summary

The study aims to investigate the effect of using a multifunctional baby carrier with rocking, safe swaddling, and white noise features on physiological parameters, crying, and sleep status in infants aged 0-3 months who have undergone congenital heart surgery. It is planned to be conducted in a randomized controlled crossover design. Following congenital heart surgery, the use of sedative interventions in the high-stress environment of the intensive care unit has a significant effect on preserving the energy reserves necessary for the infant's growth and development. Using a sensitive and soothing mobile crib to assist in the postoperative care of infants who have undergone congenital heart surgery is a potential opportunity for the infant, nurse, and parent. The combined application of swaddling, sound, and movement reduces the baby's fussiness and has a calming effect on their physiological activation.

Infants who underwent heart surgery between 0-3 months and were followed up in a multi-purpose baby carrier (swaddling, white noise, and rocking) compared to infants in the follow-up experimental group, compared to infants in the control group who were only swaddled;

Hypothesis 1: The heart rate is lower. Hypothesis 2: Blood pressure is lower. Hypothesis 3: Oxygen saturation levels are higher. Hypothesis 4: Sleep durations are longer. Hypothesis 5: Pain scores are lower.

Read the detailed description

This thesis study was designed to investigate the effect of using a multifunctional baby carrier with rocking, safe swaddling, and white noise features on physiological parameters, pain, crying, and sleep status in infants aged 0-3 months who underwent congenital heart surgery.

The sample size for the study, which is a 2x2 crossover design, was calculated using power analysis a large effect size and 80% power, resulting in a sample size of 52. Infants will be assigned to groups using simple randomization.

The dependent variables of the study are the infant's heart rate, blood pressure, oxygen saturation, sleep status, pain scale score, and crying duration. The independent variables are: the baby's gender, the baby's age, the postoperative day, the time spent at home with the parent, swaddling, white noise, and rocking.

Research groups: 1. Swaddling group (control), 2. Swaddling combined with rocking and white noise feature in a multifunctional primary cradle group.

In the crossover design, two groups were defined: Group A and Group B, where interventions were applied in different orders.

The data collection tools used in the study were the Infant Information Form, Infant Intervention Monitoring Form, Neonatal Pain, Agitation, and Sedation Scale (N PASS), Pediatric Sequential Organ Failure Assessment Score (pSOFA), Informed Consent Form-Parent Form, monitor , actigraph, stopwatch, decibel meter, swaddling cloth, and multi-functional baby carrier crib will be used as data collection tools in the study. Research data will be analyzed using the Statistical Package for Social Sciences (SPSS) program.

The safety of patients' vital sign data will be ensured through graphs. Pain assessment using the N-PASS scale will be evaluated by the same two observers, and inter-observer agreement will be examined.

03

Conditions studied

  • Congenital Heart Surgery

Keywords

  • nursing
  • pain
  • sleep
  • congenital heart defect
  • surgery
04

Who can participate

Ages eligible
1 Day to 3 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Babies born at 38 weeks or later
  • Babies aged 0 to 3 months after birth
  • No illness other than congenital heart disease
  • Who has undergone surgery for the first time due to congenital heart disease
  • Whose clinical condition is stable (PSOFA score below 8 points)
  • Infants with stable thermoregulation

Exclusion criteria

Exclusion Criteria:

  • Babies born before 38 weeks of pregnancy
  • Babies older than 3 months
  • The presence of other chromosomal or neurological disorders and syndromes in the infant
  • Those who have undergone two or more surgeries due to congenital heart disease
  • pSOFA score above 8 points
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Active comparator
    Group A

    Group A (26 babies) : 1. Monitoring in a multifunctional baby carrier for the first 3 hours (experiment) 2. Monitoring in an open incubator for the next 3 hours (control)

    Other: Multifunctional Baby Carrier

  • Active comparator
    Group B

    Group B (26 babies) : 1. Monitoring in an open incubator for the next 3 hours (control) 2. Monitoring in a multifunctional baby carrier for the first 3 hours (experiment)

    Other: Multifunctional Baby Carrier

Interventions

  • OtherMultifunctional Baby Carrier

    The study will be conducted using a randomized controlled crossover design. Infants will be assigned to either group A or group B using a simple randomization method. The infant will be assigned to the control and experimental groups according to the order of initiation within the group to which the infant belongs. Since the study is cross-over in design, infants in both groups (Group A and Group B) will be included in both the experimental group and the control group. Each baby will be monitored for a total of 6 hours. Group A (26 babies): 1. Monitoring in a multifunctional main cradle during the first 3 hours (experiment) 2. Monitoring in an open incubator wrapped for the second 3 hours (control) Group B (26 babies): 1. Monitoring in an open incubator wrapped for the second 3 hours (control) 2. Monitoring in a multifunctional main cradle during the first 3 hours (experiment)

06

What researchers measure

Primary outcomes

  1. Newborn Pain, Agitation and Sedation Scale (N PASS Scale)

    Term and preterm newborns are used for the purpose of evaluating postoperative pain/agitation and sedation. The total pain score ranges from 0 to +11. A high score indicates significant pain.

    Time frame: 6 hours

  2. Sleep-Wake Status Measurement Device (Actigraphy)

    It is used to monitor babies' sleep-wake cycles.

    Time frame: 6 hours

Secondary outcomes

  1. Pediatric Sequential Organ Failure Assessment Score (pSOFA)

    It is used to measure the severity of the disease and determine mortality. The lowest score is 0 and the highest score is 28 points. It is stated that mortality increases as the score increases. The Pediatric Sequential Organ Failure Assessment Score cutoff point distinguishing mortality is specified as 8 points. For this reason, infants with a pSOFA score below 8 points will be included in our study.

    Time frame: 6 hours

07

Study locations

1 site
  • Health Sciences University Dr. Siyami Ersek Chest, Heart, and Vascular Surgery Education and Research Hospital
    Istanbul, Üsküdar 34668, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — The consent forms stated that the confidentiality of the information would be protected and that it would be used only for the evaluation of the data in this study without identifying information.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Aug 2027, 14 months later.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 14 months is above that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2025
First posted
Jan 6, 2026
StartEst.
Jun 2026
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2028
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07319858
Responsible party
Aynur Baykal (PHD STUDENT, Istanbul University - Cerrahpasa) — Principal investigator
First posted
Jan 6, 2026
Start date
Jun 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Aug 2028 (estimated)
Last update
Apr 21, 2026

Study contacts

Aynur Baykal, Phd Student
Contact
aynur.baykal10@ogr.iuc.edu.tr
+90 538 471 39 71
Birsen Mutlu, Assc prof
Contact
bdonmez@iuc.edu.tr
+90 532 682 68 62
Birsen Mutlu, Assc prof
study director · Istanbul University - Cerrahpasa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion